Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 263 publications
Clinics and Clicks: Optimizing Hematology Care Delivery and Workflows in the Digital Era.
Journal: JCO oncology practice
Published: August 07, 2026
Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.
Journal: American journal of hematology
Published: July 11, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
Journal: American journal of hematology
Published: June 25, 2026
Clinical and Prognostic Significance of CEBPA Mutations in Myelodysplastic Syndromes.
Journal: Cancers
Published: June 06, 2026
Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia.
Journal: Blood cancer journal
Published: May 27, 2026
Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.
Journal: American journal of hematology
Published: May 13, 2026
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.
Journal: American journal of hematology
Published: May 12, 2026
Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.
Journal: Haematologica
Published: April 24, 2026
Menin Inhibition in Acute Myeloid Leukemia: Rewiring Leukemic Transcriptional Networks.
Journal: International journal of molecular sciences
Published: March 23, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.
Journal: Blood cancer journal
Published: March 13, 2026
Characteristics of clonal cytopenia of undetermined significance in the presence of ZRSR2 mutations.
Characteristics of clonal cytopenia of undetermined significance in the presence of ZRSR2 mutations.
Journal: Haematologica
Published: February 26, 2026
Last Updated: 09/26/2026